Thalidomide with continuous low-dose dexamethasone for multiple myeloma [3]

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1323-

  Gardyn, Joseph ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PULSE THERAPY; HUMAN; LETTER; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT FAILURE; DRUG ADMINISTRATION; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 14544268999     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.690     Document Type: Letter

References (7)

1. Dimopoulos MA, Anagnostopoulos A, Weber D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21:4444-4454, 2003
2. Alexanian R, Haut A, Khan AU, et al: Treatment for multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680-1685, 1969
3. Berenson JR, Crowley JJ, Grogan TM, et al: Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99:3163-3168, 2002
4. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
5. Tiplady CW, Summerfield GP: Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 111:381, 2000
6. Myers B, Grimley C, Dolan G: Thalidomide and low-dose dexamethasone in myeloma treatment. Br J Haematol 114:245, 2001
7. Stewart AK, Chen C, Howson-Jan K, et al: A multi-center randomized phase two trial of thalidomide and prednisone as maintenance therapy for multiple myeloma following autologous stem cell transplant. Hematol J 4:S208, 2003 (abstr 272; suppl)